AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9575643
Drug: Neurobex tablets
RxNorm normalized name: lidocaine hydrochloride Topical Cream [Neuromed]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurobex tablets
Trial: 8417806
Drug: rHuEPO (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (400 to 1,500 U per kg twice daily [BID] per week)
Trial: 8417806
Drug: Open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label rHuEPO administration
Trial: 2847454
Drug: 10% glucose
RxNorm normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glucose infusion with phosphate buffer (10 mmol phosphate buffer/l)
Trial: 2847454
Drug: 10% glucose
RxNorm normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glucose infusion without phosphate supplement
Trial: 31353479
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of racemic carvedilol 25 mg (CAR)
Trial: 31353479
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of racemic lercanidipine 20 mg (LER)
Trial: 31353479
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of CAR plus LER
Trial: 26043025
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg po daily
Trial: 23602424
Drug: Gentamicin solution
RxNorm normalized name: gentamicin Injectable Solution
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin solution lavage (Group 2)
Trial: 20541841
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day donepezil hydrochloride
Trial: 16813139
Drug: Toothbrush T2
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothbrush T2 (Oral B Advantage Control Grip - Oral B)
Trial: 9100160
Drug: Libido (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Libido (3 g twice daily)
Trial: 8468765
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Trial: 8512477
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (1 mg/kg per day for 14 days)
Trial: 8468765
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for 14 days
Trial: 3963356
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg nalbuphine
Trial: 29461920
Drug: Creating Change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creating Change (CC)
Trial: 22385472
Drug: Acotiamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acotiamide (100 mg t.i.d.)
Trial: 20446587
Drug: Non-aspirin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin (control group)
Trial: 10235086
Drug: Trapidil 300
RxNorm normalized name: trapidil
DrugBank: Trapidil (DB09283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil 300 mg/day
Trial: 12895190
Drug: Clomethiazole (68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomethiazole (68 mg kg(‐1) as a three-phase i.v. infusion over 24 h)
Trial: 28825195
Drug: CIM treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIM treatments (≥4 treatments, ≤30 days apart)
Trial: 28825195
Drug: CIM treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIM treatments (AIC group)
Trial: 18489634
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oxycodone/650 mg acetaminophen
Trial: 18489634
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocodone/650 mg acetaminophen
Trial: 18489634
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hydrocodone/325 mg acetaminophen
Trial: 8690107
Drug: GH‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH‐releasing hormone (GH‐RH) (1 mg/kg body weight)
Trial: 8690107
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg by mouth)
Trial: 8690107
Drug: Arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine (30 g infused IV over a 30‐minute period)
Trial: 8690107
Drug: Insulin growth
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin growth factor‐I levels
Trial: 29171557
Drug: Supervised structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised structured aerobic exercise training programme, routine medication and dietary plan for 25 weeks at 3 days per week
Trial: 15754699
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with oral laxative (lactulose 66.7%), metronidazole, and topical glyceryl-trinitrate ointment at 0.2% pre and postoperative
Trial: 11600528
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release recombinant human GH at 1.5 mg/kg once monthly
Trial: 11600528
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release recombinant human GH at 0.75 mg/kg twice monthly
Trial: 2213286
Drug: Thiazide with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide with potassium-sparing agent
Trial: 2213286
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive agents
Trial: 44015
Drug: Thioproperazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioproperazine (3 x 3 mg/day)
Trial: 44015
Drug: Tiapride (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (3 x 100 mg/day)
Trial: 31605208
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water baths (20 g/L)
Trial: 31605208
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water baths (40 g/L)
Trial: 31605208
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water baths (60 g/L)
Trial: 31327147
Drug: 0.5% Carbomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Carbomer 980 Gel
Trial: 27522605
Drug: Seabuckthorn seed
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seabuckthorn seed oil at a daily dose of 0.75 ml for 30 days
Trial: 24469972
Drug: 300,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300,000 IU intramuscular cholecalciferol
Trial: 24469972
Drug: 25,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25,000 IU oral cholecalciferol monthly
Trial: 22930004
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin 0.2 mg) followed by 1500 IU hCG 35 h after triggering final oocyte maturation and standard luteal phase support (Protocol B)
Trial: 22930004
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin 0.2 mg) and standard luteal phase support (Protocol C)
Trial: 22930004
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin 0.2 mg) without luteal phase support (Protocol D)
Trial: 10597869
Drug: Ebastine 10mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10mg once daily for 2 to 3 weeks
Trial: 10597869
Drug: Ebastine 20mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20mg once daily for 2 to 3 weeks
Trial: 10597869
Drug: Ebastine 10mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10mg twice daily for 3 weeks
Trial: 10597869
Drug: Ebastine 20mg
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20mg once daily for 3 weeks
Trial: 7703058
Drug: Vein patch
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein patch closure
Trial: 23549516
Drug: Metipranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metipranolol (10 mg twice per day)
Trial: 23405020
Drug: Preoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative physical therapy (respiratory and global exercises) for 2-3 weeks before surgery
Trial: 23405020
Drug: Preoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative physical therapy
Trial: 23405020
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (preoperative physical therapy)
Trial: 21989099
Drug: Weight monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight monitoring and recording (measured, recorded, and announced twice a week for 3 months)
Trial: 18829219
Drug: Balneotherapy associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy associated with patient education (spa treatment course in La Léchère) consisting of four balneology sessions per day, six days a week for three weeks, and three educational workshops.
Trial: 18829219
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received spa treatment starting at day 365 (after the treatment group).
Trial: 9218070
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (300 mL)
Trial: 9218070
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (300 mL)
Trial: 8525856
Drug: Overall group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall group (Moclobemide and Sertraline)
Trial: 2492322
Drug: Continuous nitroglycerin
RxNorm normalized name: nitroglycerin Extended Release Oral Tablet [Nitrocontin Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nitroglycerin patches (10 mg/day)
Trial: 2492322
Drug: Intermittent nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nitroglycerin patches (10 mg/day) for 18 h/day with 6 h off
Trial: 2492322
Drug: Intermittent nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nitroglycerin patches (10 mg/day) for 14 h/day with 10 h off
Trial: 2492322
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (10 h off)
Trial: 30924702
Drug: SPN-812 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 300 mg/day
Trial: 30924702
Drug: SPN-812 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 400 mg/day
Trial: 25227967
Drug: Initial high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial high-dose prednisolone combination therapy using COBRA regimen (methotrexate and sulfasalazine)
Trial: 25227967
Drug: COBRA-light variation
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-light variation of COBRA combination therapy
Trial: 25227967
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate and infliximab combination therapy
Trial: 21777013
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg/day, uptitrated to 40 mg/day or combined with HCTZ 40/12.5 mg/day or 40/25 mg/day
Trial: 11207321
Drug: IC14 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC14 (1 mg/kg over 1 h)
Trial: 3129273
Drug: Combined insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined insulin and glibenclamide (Euglucon N)
Trial: 3129273
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (placebo)
Trial: 29795403
Drug: 2-mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg dose of nicotine
Trial: 27988164
Drug: Single-dose interscalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose interscalene block and general anesthesia (SISB/GA)
Trial: 21041606
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride treatment
Trial: 21041606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine and cognitive behavioral therapy
Trial: 9412795
Drug: Triptorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.75 mg i.m.)
Trial: 16359772
Drug: Leuprolin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolin (3.75 mg i.m.)
Trial: 14521759
Drug: IL-2 +
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 + 3PaZ(TH)L(2)VE(AK) + 4PaL(2)V
Trial: 14521759
Drug: 3PaZ(TH)L(2)VE(AK)/4PaL(2)V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3PaZ(TH)L(2)VE(AK)/4PaL(2)V
Trial: 8799270
Drug: Gas chromatography/combustion/carbon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gas chromatography/combustion/carbon isotope ratio mass spectrometry (GC/C/IRMS) analysis of urinary steroids
Trial: 1361356
Drug: Vecuronium (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.08 mg kg‐1)
Trial: 26586300
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) applied to one side of the face post-surgery.
Trial: 23008295
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate
Trial: 19952863
Drug: HPV‐6/11/16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV‐6/11/16/18 vaccine
Trial: 17636242
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories containing 2.5 mg bromocriptine mesthylate with pluronics and bioadhesive agents, once daily for 1 month
Trial: 17636242
Drug: Commercial 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial 2.5 mg bromocriptine mesthylate tablets inserted vaginally, once daily for 1 month
Trial: 12146001
Drug: Exemestane 10
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane 10 mg/day
Trial: 12146001
Drug: Total group
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total group (10 mg + 25 mg)
Trial: 10413640
Drug: Efegatran at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efegatran at 1.2 mg. kg(‐1). h(‐1)
Trial: 10413640
Drug: Efegatran (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efegatran (various doses)
Trial: 10413640
Drug: Efegatran at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efegatran at levels of at least 0.63 mg. kg(‐1). h(‐1)
Trial: 7768238
Drug: 6.9% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9% CHO solution
Trial: 7768238
Drug: 5.5% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5% CHO solution
Trial: 7306430
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg three times daily and 400 mg at night for 6 days
Trial: 19203712
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (0, 15 or 30 mg Zn per day for 6 months)
Trial: 19203712
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 mg Zn per day for 6 months)
Trial: 11855146
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) in combination with corticosteroid (prednisone + danazol)
Trial: 9771080
Drug: Latanoprost (0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost (0.005% xalathane solution)
Trial: 9771080
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of latanoprost with pilocarpine + timolol
Trial: 7930743
Drug: Artesunate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (10 mg/kg over 3 days) plus mefloquine (25 mg/kg)
Trial: 7930743
Drug: High-dose mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mefloquine alone
Trial: 7930743
Drug: Mefloquine on
RxNorm normalized name: Mefloquine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine on day 2 of treatment
Trial: 22428914
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Glucobay® 100 mg tablet)
Trial: 22428914
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (generic acarbose 100 mg tablet)
Trial: 12722964
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg daily
Trial: 8469785
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg three times daily for 12 weeks
Trial: 26850676
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (orally inhaled salbutamol)
Trial: 26850676
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (orally inhaled salbutamol)
Trial: 22382087
Drug: Integral doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral doses
Trial: 21102969
Drug: OM-ER 15
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM-ER 15 mg
Trial: 21102969
Drug: OM-ER 30
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM-ER 30 mg
Trial: 10224679
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy laser radiation treatment in addition to routine antibiotic therapy
Trial: 10224679
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic therapy
Trial: 2004544
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 125 mg twice daily
Trial: 24067745
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 ml, three times daily for 3 days)
Trial: 23469595
Drug: Shuangshen Tongguan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuangshen Tongguan Capsule (STC), 4 pills each time, three times daily
Trial: 30944162
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of peroral metronidazole/amoxicillin antibiotic treatment
Trial: 7168635
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic treatment (control group)
Trial: 8756815
Drug: Placebo (excipient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (excipient only) inhalation
Trial: 2017519
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment (chronic)
Trial: 31068182
Drug: Normal platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal platelet counts (≥150 to <300 × 10^9/L)
Trial: 27857631
Drug: Passive soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive soft tissue therapy
Trial: 27857631
Drug: Active soft
RxNorm normalized name: Nature's Way Petadolex Pro-Active Softgels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active soft tissue therapy
Trial: 20965712
Drug: Beclomethasone/formoterol (200/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone/formoterol (200/12 μg)